Posted: April 11, 2022
-Contributed by Abi Kasberg, PhD Von Willebrand disease (VWD) is an inherited bleeding disease that clinically presents with extended bleeding times following wounds, surgeries, nosebleeds, or during menstruation. VWD affects approximately 0.1% of people and is considered to be the most common bleeding disorder (Keesler and Flood 2017). Von Willebrand factor (vWF) is a multimer…
Posted: March 25, 2022
David L. McGlasson, MS, MLS(ASCP) Before reading this blog post, I invite the viewer to read the article by Abi Kasberg, PhD posted August 21, 2021 titled Thrombotic Thrombocytopenic Purpura (TTP) Clinical Trials: Targeting the needs left by current treatment options. It’s a great review of current methods to address ADAMTS13 deficiency and discusses the…
Posted: December 17, 2021
THE NEW NOVEL ANTICOAGULANTS XI(a) and XII(a). THE CONTACT FACTOR INHIBITORS: Battling thromboembolism. David L. McGlasson, MS, MLS(ASCP) INTRODUCTION Thromboembolism is a leading cause of mortality and morbidity. Treatment with anticoagulants is prescribed, but balancing bleeding and clotting has been a challenge. In the 1940s, unfractionated heparin (UFH) became available for use by intravenous or…
Posted: September 27, 2021
A Trio of Biomarkers: A Novel Multivariate Model to Detect DILI & Liver Damage -Contributed by Abi Kasberg, PhD While maybe underappreciated, Drug-induced liver injury (DILI) is a condition with significant impact on the medical world. DILI is the leading cause of acute liver failure and is frequently responsible for the termination and withdrawal of…
Posted: September 27, 2021
Clot Club – ISTH 2021 David L. McGlasson, MS, MLS(ASCP) Attending the International Society of Thrombosis and Hemostasis 2021 virtually from July 17-21, 2021 was quite a challenge this year. There were lots of information ranging from clinical, to what I would call “futuristic” research, that we might not see put into clinical practice for…